In its latest 13F filing for the third quarter, GDS Wealth Management disclosed a 10.7% reduction in its holdings of UnitedHealth Group shares, selling 5,297 shares and ending the period with 44,252 shares valued at approximately $15.28 million. This adjustment reflects a recalibration of the firm’s healthcare allocation during a quarter marked by broader sector volatility and cost-pressure concerns within the Medicare Advantage business.

Several smaller institutions entered or expanded positions in UnitedHealth during the second and third quarters. LFA Lugano Financial Advisors and Sagard Holdings Management each established new stakes valued near $25,000 and $29,000 respectively, while Grey Fox Wealth Advisors and Islay Capital Management initiated positions of roughly $33,000 and $31,000. Riggs Asset Management notably increased its holding by 69.4%, acquiring an additional 43 shares to bring its total to 105 shares worth $33,000.

A recent flurry of research notes has tilted positive for UnitedHealth Group. Jefferies raised its target by over 28%, Goldman Sachs launched coverage with a “buy” call, and UBS boosted its target by 14%, all citing resilient membership trends and continued margin improvement drivers. Piper Sandler trimmed its target modestly but maintained an overweight stance, while Mizuho upgraded its view based on favorable Medicare Advantage policy developments. Collectively, one analyst rates the stock as a strong buy, seventeen as buy, nine hold, and two sell, for a consensus of Moderate Buy.

UnitedHealth Group’s quarterly dividend of $2.21 per share, paid on December 16 to holders of record as of December 8, corresponds to an $8.84 annualized distribution and a yield near decade-high levels. With a payout ratio below 50% and normalized free cash flow exceeding $18 billion over the past four quarters, the company’s capacity to sustain and potentially grow its dividend remains strong, even as it navigates cost pressures and regulatory scrutiny.